How to Document Nephrology Patient Visits and Chronic Kidney Disease Management Plans

A practical documentation guide for nephrologists, NPs, and PAs. Covers CKD staging with GFR and albuminuria categories, dialysis management notes, electrolyte and fluid documentation, AKI consult notes, transplant evaluation records, vascular access documentation, and CMS ESRD Quality Incentive Program reporting requirements.

Why Nephrology Documentation Is Uniquely Demanding

Most medical specialties follow a fairly predictable visit note structure. Nephrology does not. A single nephrologist may see a patient in CKD Stage 3 for a routine follow-up, then immediately turn to an AKI consult in the ICU, then review a dialysis patient's monthly labs, then conduct a pre-transplant evaluation. Each of those encounters has a different documentation purpose, a different regulatory framework, and a different risk profile.

The challenge is not just complexity within a single visit. It is longitudinal complexity: managing a patient through years of CKD progression means your notes collectively tell a story of a disease that is slowly changing. When that patient eventually starts dialysis or pursues transplant, every prior note becomes relevant. Auditors, transplant committees, and insurance reviewers will look back at your documentation to understand how the disease progressed and what decisions were made along the way.

This guide walks through the specific documentation requirements for nephrology clinical encounters. It is written for nephrologists, nurse practitioners, and physician assistants who manage patients across the full spectrum of kidney disease.

CKD Staging Documentation: Getting GFR and Albuminuria Right

The foundation of any nephrology note for a CKD patient is accurate staging. The Kidney Disease: Improving Global Outcomes (KDIGO) classification uses two dimensions: glomerular filtration rate (GFR) category and albuminuria category. Documenting both is not optional. A note that records only the eGFR number without the staging context leaves a clinical and documentation gap.

GFR Categories

G1: eGFR ≥ 90 mL/min/1.73 m²
G2: eGFR 60-89 mL/min/1.73 m²
G3a: eGFR 45-59 mL/min/1.73 m²
G3b: eGFR 30-44 mL/min/1.73 m²
G4: eGFR 15-29 mL/min/1.73 m²
G5: eGFR < 15 mL/min/1.73 m² (kidney failure)

Albuminuria Categories

A1: < 30 mg/g creatinine (normal to mildly increased)
A2: 30-300 mg/g creatinine (moderately increased)
A3: > 300 mg/g creatinine (severely increased)

Example of properly staged CKD documentation:

"Ms. Ortega, 64-year-old female with type 2 diabetes mellitus and hypertension, presents for routine CKD follow-up. Current eGFR: 38 mL/min/1.73 m² (down from 42 at last visit six months ago). Urine albumin-to-creatinine ratio: 210 mg/g. KDIGO staging: CKD G3b A2. Disease progression rate approximately 2 mL/min/year over the past 18 months. This trajectory warrants review of current management and patient education regarding future renal replacement therapy options."

That last sentence matters. Documentation of CKD progression rate over time gives context that a single eGFR value cannot provide. Calculate and record the slope when you have enough data points to do so meaningfully.

What Triggers Documentation of RRT Education

When a patient reaches CKD G4 or G5, document that you have had the conversation about renal replacement therapy (RRT) options: hemodialysis, peritoneal dialysis, transplant, and conservative management. This education conversation is both a clinical responsibility and a documentation requirement for many payers. Log:

That the conversation occurred
Which modalities were discussed
The patient's understanding and preferences
Referrals made (nephrology social work, transplant center, vascular surgery for access planning)

Documenting Dialysis Initiation

The decision to initiate dialysis is one of the highest-stakes clinical decisions a nephrologist makes. Your documentation at this transition point needs to reflect both the clinical indication and the shared decision-making process.

What Dialysis Initiation Notes Must Cover

Clinical indication documentation:

Current eGFR and trajectory
Symptomatic uremia, if present (document specific symptoms: anorexia, nausea, pericarditis, encephalopathy, fluid overload refractory to diuretics)
Lab findings supporting initiation: blood urea nitrogen (BUN), creatinine, potassium, bicarbonate, and phosphorus trends
Why initiation is occurring now versus earlier or later

Shared decision-making documentation:

Modality selected (hemodialysis vs. peritoneal dialysis) and why
Patient's involvement in the decision
Alternatives discussed (including conservative management, if appropriate)
Whether patient has decision-making capacity, and how family or proxy was involved if not

Example:

"Mr. Vasquez, 72-year-old male with CKD G5 secondary to hypertensive nephrosclerosis, presents with worsening uremic symptoms over the past three weeks: anorexia with 6 lb weight loss, progressive fatigue limiting daily activities, and lower extremity edema not responding to furosemide 80 mg BID. eGFR today: 9 mL/min/1.73 m². BUN 98 mg/dL, creatinine 6.4 mg/dL, potassium 5.7 mEq/L, bicarbonate 17 mEq/L. Given symptomatic uremia and inability to further optimize medical management, dialysis initiation is clinically indicated. After extended discussion with patient and his daughter, patient has chosen in-center hemodialysis (HD). Peritoneal dialysis was discussed; patient declined due to concerns about home management. Conservative kidney management was also presented; patient expresses a desire to continue treatment. Referral to interventional radiology for AVF creation previously placed; right arm radiocephalic AVF placed three months ago, maturing adequately per last Doppler. Initiating HD via right internal jugular tunneled catheter today pending AVF maturation. Nephrology social work consulted for transportation and financial assistance coordination."

Ongoing Dialysis Management Notes

Once a patient is established on dialysis, documentation shifts to a monthly rhythm (for HD patients) coordinated with the dialysis facility's ESRD monthly note requirements.

Core Elements of a Hemodialysis Management Note

Dialysis adequacy: Document Kt/V (target ≥ 1.2 for thrice-weekly HD). If below target, document why and what was changed.
Dry weight and fluid status: Record target dry weight and whether it has been adjusted, and why.
Vascular access status: Document access type, any complications, patency findings, and planned interventions.
Anemia management: Hemoglobin value, current erythropoiesis-stimulating agent (ESA) dose and route, iron stores (ferritin and transferrin saturation (TSAT)), and any dose adjustments with rationale.
Mineral metabolism: Calcium, phosphorus, parathyroid hormone (PTH), and current phosphate binder and vitamin D analog doses.
Medications: Full medication reconciliation, including dialysis-specific medications and any removed by HD.
Hospitalizations since last visit: Document any admissions, their cause, and relevance to current management.

Example of anemia management documentation:

"Hemoglobin this month: 9.8 g/dL (target 10-11.5 g/dL). Ferritin: 240 ng/mL. TSAT: 18%. Iron stores adequate. Current epoetin alfa dose: 4,000 units IV with each HD session three times weekly. Given hemoglobin below target with adequate iron stores, increasing epoetin alfa to 6,000 units IV per session. Will recheck hemoglobin in 4 weeks. Reviewed CMS ESRD QIP hemoglobin targets with patient; patient understands the goal range and reasons for adjustment."

Vascular Access Documentation for Hemodialysis Patients

Vascular access is one of the most clinically and legally important documentation areas in hemodialysis. Poor access documentation is a common audit finding and a source of preventable complications.

At each HD facility visit note:

Current access type: arteriovenous fistula (AVF), arteriovenous graft (AVG), or tunneled central venous catheter (TCVC)
Access site appearance (any redness, swelling, drainage, or pain)
Blood flow rates achieved and any difficulty with cannulation
Whether a catheter lock solution was applied and which agent

When problems arise:

Specific problem description: low flow, clotting, infection signs, failure to mature (for new AVF)
Interventions ordered or performed: Doppler ultrasound, fistulogram, thrombectomy, catheter exchange
Result of the intervention and follow-up plan

Example for a catheter infection concern:

"Ms. Huang, 58-year-old female on HD via right IJ tunneled catheter (placed 14 months ago, AVF not yet created due to inadequate vessels). Patient reports catheter exit site redness and mild tenderness since two days ago, no fever. Exam: erythema approximately 1.5 cm around exit site, no purulence, no tunnel tenderness, no systemic signs of infection. Blood cultures drawn today (two sets: one from catheter, one peripheral). Catheter exit site swab sent for culture. Empiric treatment initiated with vancomycin IV after cultures drawn. Dose weight-based, HD clearance accounted for per pharmacy consultation. Exit site care instructions reviewed with patient. Will reassess in 48 hours pending culture results. Vascular surgery referral to be placed to discuss options for permanent access given prolonged catheter dependence."

Document the plan for eventually transitioning to a permanent access, even if that plan is "continue to attempt." Catheter-dependent patients without a documented access plan are an audit red flag.

Electrolyte and Fluid Management Documentation

Electrolyte abnormalities in nephrology are rarely isolated findings. They are windows into what the kidneys are and are not doing, and they frequently require documentation of the clinical reasoning behind treatment decisions, not just the values and orders.

Hyperkalemia Documentation

For hyperkalemia in CKD patients, document:

The potassium value and the trend (is this new, worsening, chronic)
EKG findings if obtained (even if normal: "EKG performed given potassium of 6.1 mEq/L; no peaked T-waves or PR prolongation identified")
Cause assessment: dietary, medication-related (ACE inhibitors, ARBs, potassium-sparing diuretics, trimethoprim), acidosis, constipation, inadequate dialysis clearance
Treatment initiated and the rationale (dietary counseling, medication adjustment, patiromer or sodium zirconium cyclosilicate initiation, dialysis prescription adjustment)
Follow-up plan with specific timeline

Metabolic Acidosis Documentation

Metabolic acidosis is ubiquitous in advanced CKD and requires documentation that links the bicarbonate value to the clinical context:

"Serum bicarbonate: 18 mEq/L (previous 21 mEq/L three months ago). Anion gap: 14. Worsening acidosis likely reflects CKD progression and decreased acid excretion. Dietary protein modestly high per dietary consult from last visit. Initiating sodium bicarbonate 650 mg TID. Target serum bicarbonate ≥ 22 mEq/L. Evidence supports correction of acidosis to slow CKD progression and improve nutritional status. Follow-up bicarbonate in six weeks."

AKI Consult Documentation

Acute kidney injury (AKI) consults require a note structure distinct from your outpatient CKD documentation. The AKI consult note must accomplish several things quickly, because the clinical team is often waiting for guidance.

AKI Consult Note Structure

Reason for consult: State it clearly. ("Consult requested by ICU team for AKI, creatinine up from 1.1 to 3.8 over 48 hours.")

History and context: Pre-existing CKD or baseline renal function, recent nephrotoxin exposures (contrast, NSAIDs, aminoglycosides, vancomycin), hemodynamic status, fluid balance over the admission.

KDIGO AKI Staging: Document the stage explicitly.

Stage 1: Creatinine increase ≥ 0.3 mg/dL within 48h, or 1.5-1.9x baseline within 7 days
Stage 2: Creatinine increase 2.0-2.9x baseline
Stage 3: Creatinine increase ≥ 3x baseline, or creatinine ≥ 4.0 mg/dL, or initiation of RRT

Etiology workup: Document your assessment of prerenal, intrinsic renal (further divided by anatomical compartment: glomerular, tubular, interstitial, vascular), and postrenal causes. List the findings supporting your leading diagnosis. Document any diagnostic studies ordered: urinalysis with microscopy, urine sodium and creatinine (for fractional excretion of sodium (FeNa)), renal ultrasound, kidney biopsy if indicated.

Example:

"58-year-old male with no known prior kidney disease admitted for community-acquired pneumonia. Creatinine on admission 1.0 mg/dL. Now day 3: creatinine 2.8 mg/dL, urine output 400 mL over past 12 hours. KDIGO Stage 2 AKI. Patient received vancomycin 15 mg/kg q12h for 48 hours (trough levels not checked until today; trough 28 mcg/mL, supratherapeutic). Urine sodium 8 mEq/L, FeNa 0.3%, suggesting prerenal component; urine microscopy shows muddy brown casts consistent with concurrent tubular injury. Assessment: mixed prerenal and nephrotoxic (vancomycin-related) AKI. Recommendations: (1) Vancomycin dose extended, recheck trough in 36 hours; consider switch to alternative anti-MRSA agent with ID team. (2) Cautious volume resuscitation — 500 mL NS bolus, reassess hemodynamics. (3) Avoid further nephrotoxins. (4) Monitor creatinine, electrolytes, and urine output q12h. (5) Will follow daily and reassess need for RRT if no improvement in 48-72 hours."

Transplant Evaluation Documentation

Kidney transplant evaluation generates a substantial documentation burden across multiple visits and disciplines. Your role as the referring or evaluating nephrologist is to document a complete clinical picture that will inform the transplant committee.

Elements of the Transplant Evaluation Note

Transplant indication: CKD stage, underlying diagnosis, timeline of progression
Cardiovascular evaluation status: Stress testing, echocardiogram, cardiology clearance (or pending items)
Infectious disease screening: HIV, hepatitis B and C, CMV, EBV, tuberculosis (IGRA or PPD), and vaccination status
Malignancy screening: Age-appropriate cancer screening completed or pending; any prior malignancy history and oncology clearance if needed
Surgical risk assessment: Peripheral vascular disease evaluation, abdominal imaging review for surgical feasibility
Psychosocial evaluation: Social work assessment, adherence history, support system
Immunologic workup: Blood type, panel reactive antibody (PRA) level, prior sensitization events (prior transplants, pregnancies, transfusions)
Living donor evaluation status: Whether living donor is being evaluated and at what stage

Document pending items explicitly. "Cardiovascular clearance pending stress test scheduled for [date]" is far better than leaving the item blank, because it shows the committee where the evaluation stands.

CMS ESRD Quality Incentive Program Documentation

The CMS ESRD Quality Incentive Program (QIP) ties dialysis facility payments to quality metrics. While the primary QIP documentation responsibility sits with the facility, nephrologists who serve as medical directors or attending physicians contribute to the underlying clinical records that QIP reporting depends on.

Key QIP Metrics That Require Physician-Level Documentation

Kt/V adequacy: Document monthly Kt/V values and any corrective actions when below target.
Hemoglobin management: Document ESA doses and adjustments. The QIP no longer directly measures hemoglobin values but ESA prescribing patterns remain scrutinized.
Vascular access: Document the type of access used at each HD session (AVF vs. graft vs. catheter). Facilities are measured on AVF and AVG rates; physician notes contribute to this data.
Mineral metabolism: Calcium, phosphorus, and PTH values should be documented with clinical responses when values are out of target range.
Patient safety reporting: Document any dialysis-related events, including bloodstream infections, access complications, and hospitalizations, with enough clinical detail to support facility reporting to the CDC NHSN.

The practical implication: your monthly dialysis patient notes need to capture the specific data points that feed QIP reporting. A note that says "labs reviewed, patient doing well" does not serve this purpose.

Documenting Progressive Disease Over Years of Care

Long-term CKD management creates a documentation challenge that is almost unique to nephrology: your notes must work individually and also as a coherent longitudinal record. When a patient you have been managing for six years finally reaches ESRD, that entire record may be reviewed.

Strategies for Longitudinal Documentation Coherence

Use consistent staging language. Always document the KDIGO stage in every visit note, not just at initial diagnosis. A reviewer tracing disease progression needs to find that staging information in each note.

Document clinical decisions explicitly. When you decide not to initiate dialysis despite an eGFR of 12, document why: "Patient asymptomatic, tolerating CKD well, recent dietary adjustments have stabilized eGFR over the past three months. Decision to continue close monitoring and defer RRT discussion pending next eGFR." An undocumented decision looks like a missed one.

Note the reasoning behind medication changes. In nephrology, medication reconciliation for patients with advanced CKD is especially complex. Doses change as GFR declines. Drugs accumulate. Document the basis for every significant medication change, particularly for renally-cleared medications.

Cross-reference prior notes when relevant. "Since last visit" or "compared to six months ago" in your assessment section creates the longitudinal thread that a reviewer needs to follow your clinical reasoning.

Common Documentation Mistakes in Nephrology

1. Staging without both dimensions. Recording eGFR without the albuminuria category, or vice versa, produces an incomplete KDIGO stage. Both values belong in every CKD note.

2. Dialysis adequacy without a clinical response. A Kt/V of 1.0 documented with no follow-up action implies either you did not notice or you did not care. Document what you changed or why you did not change anything.

3. Vascular access notes that describe only appearance. Access notes limited to "catheter intact" or "fistula patent" are not sufficient. Document flow, any problems at the session, and the plan for access improvement or transition.

4. Undocumented RRT education timing. If a patient reaches G4 and there is no note documenting an RRT education conversation, that is a gap an auditor will find. The conversation does not need to be elaborate, but it needs to be in the record.

5. AKI consult notes without explicit staging. "AKI" as a diagnosis without KDIGO staging tells the consulting team almost nothing clinically and does not support accurate billing or risk stratification.

6. Transplant evaluation notes with implicit rather than explicit pending items. "Cardiovascular workup in progress" is weaker than listing exactly what has been done and what remains.

Putting It Together: Note Templates for Nephrology

Nephrology encompasses so many distinct visit types that building separate templates for each, rather than adapting a generic SOAP note, makes a real difference in documentation efficiency. A CKD follow-up template has different required fields than an AKI consult note or a monthly dialysis management note. NotuDocs lets you build distinct templates for each encounter type, so the required fields for ESRD QIP reporting, KDIGO staging, or AKI workup are always present in the right note and never appear where they do not belong. Your clinical reasoning fills each section; the structure ensures nothing is missed.

Clinical indication for initiation documented (symptomatic or eGFR-based)
Specific uremic symptoms listed if present
Lab findings supporting initiation documented
Modality selection documented with patient preference noted
Shared decision-making discussion documented
Conservative management discussed (with patient decision noted)
Vascular access plan documented
First dialysis prescription documented
Social work involvement documented

Monthly Hemodialysis Management Note

Kt/V documented with target and clinical response if below target
Dry weight documented with any adjustments and rationale
Vascular access type, status, and any complications
Hemoglobin and current ESA dose; adjustments with rationale
Iron stores: ferritin and TSAT; iron supplementation documented
Calcium, phosphorus, PTH; binder and vitamin D analog doses
Hospitalizations since last visit reviewed
Full medication reconciliation completed

AKI Consult Note

Reason for consult stated clearly
Baseline creatinine and admission creatinine documented
KDIGO AKI Stage explicitly stated
Nephrotoxin exposure assessment documented
Urine studies ordered and results documented (urinalysis, FeNa, microscopy)
Prerenal vs. intrinsic vs. postrenal assessment documented
Hemodynamic and volume status assessed and documented
Specific recommendations numbered and complete
Follow-up frequency and RRT threshold documented

Transplant Evaluation Note

Transplant indication and CKD history documented
Cardiovascular evaluation status (complete, pending, or not indicated with rationale)
Infectious disease screening status itemized
Malignancy screening status documented
Surgical risk assessment documented
Psychosocial evaluation status documented
PRA level and sensitization history documented
Living donor evaluation status documented
All pending items listed with expected completion dates

Vascular Access Note

Access type documented
Access site appearance and function documented
Blood flow rate at session documented (HD notes)
Any complication identified with specific description
Interventions ordered or performed documented
Plan for access improvement or transition documented (especially for catheter-dependent patients)

Related guides: